We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urine Test Identifies Risk of Necrotizing Enterocolitis

By LabMedica International staff writers
Posted on 30 Apr 2013
In premature babies, abnormal gut bacteria can be found days before the onset of the devastating intestinal disease known as necrotizing enterocolitis (NEC).

Examination of stool samples from preterm infants by molecular techniques and urinary metabolomic analysis has revealed differences between those at risk of NEC and those who will not develop the disease. More...


Scientists at Cincinnati Children's Hospital (OH, USA) collaborating with other institutes, studied between October 2009 and August 2010, a total of 35 preterm infants of less than 29 weeks gestational age and whose weight was less than 1,200 grams at birth, The primary analysis included 11 infants who developed NEC and 21 control infants. The infant microbiome was analyzed by postnatal periods, 4 to 9 days and 10 to 16 days.

Bacterial DNA was extracted from infant stool samples using one of two methods: phenol-chloroform or the QiaAmp DNA stool kit (Qiagen Sciences; Germantown, MD, USA). The 16S ribosomal ribonucleic acid ( rRNA) gene was amplified and sequenced using 454 FLX Titanium sequencing (454 Life Sciences, Branford, CT, USA). Urine samples were analyzed by nuclear magnetic resonance.

Babies who later went on to develop NEC had a lower diversity of gut bacteria 4 to 9 days after birth, with increased level of Firmicutes or Enterobacteriaceae, but lacked the Propionibacterium found in healthy babies. All of the babies with NEC also had unusual levels of specific bacteria. Babies whose NEC started early, between 7 to 12 days after birth had abnormally high levels of Firmicutes, while babies whose NEC started later, 19 to 31 days, had high levels of Enterobacteriaceae. No difference was found in the relative abundance of Propionibacterium between NEC and control samples collected from days 10 to 16 of life.

No urinary metabolites differed significantly among all NEC cases and controls. However, three metabolites, alanine, pyridoxine (4-pyridoxate) and histidine, significantly distinguished NEC-I and NEC-II from each other as well as one of the NEC sub-types from controls.

Alanine was significantly higher in NEC-I versus NEC-II and NEC-I versus the control samples though the metabolite did not differ between all NEC versus control samples.

Ardythe L. Morrow, PhD, the senior author of the study said, "Our data show that onset of NEC appears to be related to having abnormally high levels of specific bacteria in the gut during the first week or two of life. Our data also indicate that a simple urine test looking at levels of alanine and histidine, which appear altered by these bacteria, can be used early in life to identify babies at risk of NEC." The study was published on April 16, 2013, in the journal Microbiome.

Related Links:

Cincinnati Children's Hospital
Qiagen Sciences
454 Life Sciences



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.